EJHaem · 2026
Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia-Chromosome-Positive Lymphoblastic Malignancies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yokoyama Emi, Ota Satoshi, Sakurai Yasuo, Suzuki Toma, Miyashita Naoki, Kanaya Minoru, Izumiyama Koh, Saito Makoto, Morioka Masanobu, Mori Akio, Kondo Takeshi
Аннотация
INTRODUCTION: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin-based antibody-drug conjugate.
CASE PRESENTATION: We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without hematopoietic stem cell transplantation for Philadelphia-chromosome-positive (Ph+) lymphoblastic malignancies. Both cases developed SOS/VOD after two courses of InO. Ultrasound scoring system and pathological assessment were useful for diagnosis of SOS/VOD.
CONCLUSION: This is the first report warning of the potentially high risk of developing SOS/VOD with the combination of InO and ponatinib, both of which can induce endothelial cell damage.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
CASE PRESENTATION: We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without hematopoietic stem cell transplantation for Philadelphia-chromosome-positive (Ph+) lymphoblastic malignancies. Both cases developed SOS/VOD after two courses of InO. Ultrasound scoring system and pathological assessment were useful for diagnosis of SOS/VOD.
CONCLUSION: This is the first report warning of the potentially high risk of developing SOS/VOD with the combination of InO and ponatinib, both of which can induce endothelial cell damage.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.